Amber Cardoos

Learn More
This study explores whether inflammatory biomarkers act as moderators of clinical response to omega-3 (n-3) fatty acids in subjects with major depressive disorder (MDD). One hundred fifty-five subjects with Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) MDD, a baseline 17-item Hamilton Depression Rating Scale (HAM-D-17) score(More)
BACKGROUND Psychosocial treatments and medications both have been shown to be effective in treating major depressive disorder. We hypothesized that cognitive-behavioral therapy (CBT) would outperform medication on measures of cognitive change. METHODS We randomized depressed individuals to 12 weeks of CBT (n = 15) or escitalopram (n = 11). In an(More)
The aim of this study was to evaluate efficacy of ziprasidone monotherapy for major depressive disorder (MDD) with and without psychomotor symptoms. In accordance with the sequential parallel comparison design, 106 MDD patients (age 44.0±10.7 years; female, 43.4%) were recruited and a post-hoc analysis was carried out on 12-week double-blind treatment with(More)
In the context of the ever-increasing incarcerated population in the U.S. and our “obesity epidemic,” recent work has investigated whether incarcerated individuals are at higher risk for obesity and related diseases. We build on this scholarship by interviewing incarcerated men and women, as well as correctional facility staff to parse the barriers and(More)
Treatment-resistant depression (TRD) remains a common problem, with 29%–46% of depressed patients failing to respond sufficiently to adequate trials of antidepressant medications. Recently, several open-label clinical trials of riluzole, an antiglutamatergic drug approved by the US Food and Drug Administration (FDA) for treatment of amytrophic lateral(More)
  • 1